• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Cetuximab in non-melanoma skin cancer.
【24h】

Cetuximab in non-melanoma skin cancer.

机译：西妥昔单抗用于非黑色素瘤皮肤癌。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Non-melanoma skin cancer (NMSC) has become the most common cancer with squamous cell carcinoma (SCC) as the major cause of morbidity and mortality. REVIEW AREAS COVERED: The chimeric human-mouse monoclonal antibody Cetuximab against epidermal growth factor receptor (EGFR) has been approved for advanced head and neck cancer (HNC). Since SCC has been shown to express the EGFR, EGFR-targeted therapy is an option.A PUBMED research 2000 - 2012 have been conducted using the following items: "Non-melanoma skin cancer AND cetuximab," "cutaneous squamous cell carcinoma AND cetuximab," and "basal cell carcinoma AND cetuximab."Current evidence of cetuximab efficacy in NMSC results from a Phase II trial and case reports. Cetuximab can be combined with radiotherapy in analogy to HNC. The total response rate is almost 50% in patients with SCC. The combination with radiotherapy resulted in a complete response rate of 50%. Management of adverse reactions in SCC with particular emphasis on cutaneous toxicities is necessary. Further controlled trials are needed. EXPERT OPINION: EGFR inhibitor cetuximab is an option for recurrent or advanced SCC of skin. The combination with radiotherapy seems to be superior to cetuximab alone.
机译：非黑色素瘤皮肤癌（NMSC）已成为最常见的癌症，鳞状细胞癌（SCC）是发病率和死亡率的主要原因。综述领域：针对表皮生长因子受体（EGFR）的嵌合人鼠单克隆抗体西妥昔单抗已被批准用于晚期头颈癌（HNC）。由于已证明SCC可表达EGFR，因此可以选择针对EGFR的疗法。2000年至2012年进行的PUBMED研究使用了以下项目：“非黑色素瘤皮肤癌和西妥昔单抗”，“皮肤鳞状细胞癌和西妥昔单抗”，和“基底细胞癌和西妥昔单抗”。西妥昔单抗在NMSC中的有效性的当前证据来自II期试验和病例报告。西妥昔单抗可以与HNC类似地与放疗联合使用。 SCC患者的总缓解率接近50％。与放疗相结合，可达到50％的完全缓解率。应对SCC中的不良反应进行管理，尤其要重视皮肤毒性。需要进一步的对照试验。专家意见：EGFR抑制剂西妥昔单抗是皮肤复发或晚期SCC的一种选择。放疗联合治疗似乎优于单独使用西妥昔单抗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号